Follow-up and Surveillance

Principles of Oncologic Surveillance - Watching the Horizon

• Core Goals: Early detection of cancer recurrence (local, regional, distant), new primary malignancies, & management of treatment-related complications.
• Benefits: Aims to improve overall survival & quality of life (QoL); provides patient reassurance.
• Methods Include:
  • Regular history & physical examination (H&P).
  • Scheduled imaging (e.g., CT, MRI, PET scans).
  • Tumor markers (e.g., CEA, PSA).
  • Endoscopic procedures (site-specific).
• Frequency: Tailored to cancer type, stage, & individual risk. Typically more intensive initially (e.g., every 3-6 months for 2-3 years), then decreases.
• Key Principle: Individualized surveillance strategy is paramount.

⭐ Surveillance is most effective when it detects asymptomatic, treatable recurrences or second primary cancers.

Surveillance Tools & Techniques - The Detective's Kit

• Clinical Assessment: Cornerstone; regular history & physical exam (H&P).
• Tumor Markers (Blood Tests): Monitor trends, not just absolute values.
  • CEA: Colorectal, medullary thyroid.
  • AFP: Hepatocellular Carcinoma (HCC), non-seminomatous germ cell tumors.
  • CA 19-9: Pancreatic, cholangiocarcinoma.
  • CA-125: Ovarian cancer.
  • PSA: Prostate cancer.
  • hCG: Germ cell tumors.
• Imaging Studies: Tailored to cancer type & risk.
  • Ultrasound (USG): Initial, accessible (e.g., liver, nodes, thyroid).
  • Contrast-Enhanced CT (CECT): Chest/Abdomen/Pelvis (CAP) - standard for metastases.
  • MRI: Superior for specific sites (e.g., brain, liver, rectal cancer restaging).
  • PET-CT (FDG): Detects metabolic activity, occult recurrence, treatment response.
• Endoscopic Procedures: Direct visualization & biopsy capability.
  • Colonoscopy (Colorectal), Upper GI Endoscopy (Gastric/Esophageal), Bronchoscopy (Lung).
• Pathology: Biopsy/FNAC of suspicious lesions confirms recurrence.

⭐ PET-CT can identify occult metastases or unsuspected recurrence, changing management in approximately 15-30% of patients being re-evaluated for various cancers after primary treatment.

Site-Specific Surveillance Snippets - Cancer Case Files

• Breast Cancer (Post-Tx):
  • H&P: q3-6mo for 2yrs, q6-12mo for 3yrs, then annually.
  • Mammogram: Annually. Routine tumor markers (CEA, CA15-3) NOT recommended for asymptomatic surveillance.
  • Bone density scan: Consider if on Aromatase Inhibitors (AIs).
• Colorectal Cancer (CRC) (Post-Resection Stage II/III):
  • H&P, CEA: q3-6mo for 2yrs, then q6mo for 3yrs (total 5yrs).
  • CT C/A/P: Annually for 3-5 years (high-risk Stage II and Stage III).
  • Colonoscopy: 1yr post-op. If normal, then in 3yrs. If normal, then q5yrs.

  ⭐ Lynch syndrome: Annual colonoscopy from age 20-25 or 2-5 yrs prior to earliest family CRC diagnosis.

• Oral Cavity Cancer (Post-Tx):
  • H&P, oral exam: q1-3mo (yr1); q2-6mo (yr2); q4-8mo (yrs3-5); annually (after 5yr).
  • Imaging (CT/MRI/PET): Baseline post-Tx scan, then clinically indicated. Regular dental eval (e.g., q6mo).
• Cervical Cancer (Post-Tx):
  • H&P, pelvic exam: q3-6mo for 2yrs, q6-12mo for 3yrs, then annually.
  • Pap smear (if cervix present) or vault smear (post-hysterectomy): Follow pelvic exam schedule.

Recurrence & Survivorship Care - The Next Chapter

• Recurrence: Cancer reappearance after initial treatment-induced remission.
  • Types: Local (at primary site), Regional (lymph nodes), Distant (metastasis).
  • Detection: Vigilant follow-up (history, physical exam, imaging like PET-CT, tumor markers e.g., CEA, CA-125).
  • Management: Individualized; may involve re-surgery, salvage chemotherapy/radiotherapy, or palliative care.
• Survivorship Care Plan (SCP): Comprehensive approach for post-treatment well-being.
  • Surveillance: For recurrence, second primary malignancies.
  • Late Effects Management: Chronic pain, fatigue, lymphedema, cardiotoxicity, neurocognitive issues, psychosocial distress.
  • Health Promotion: Diet, exercise, smoking cessation.
  • Care Coordination: Oncologists, PCP, specialists.
  • Emphasis on Quality of Life (QoL) and functional recovery.

  ⭐ Most solid tumor recurrences manifest within the first 2-5 years after primary treatment completion.

High‑Yield Points - ⚡ Biggest Takeaways

• Goals: Detect recurrence (local/distant), manage sequelae, screen for second primaries.
• Frequency: Intense early (q3-6mo, 2-3 yrs), then less (annually post 5 yrs), varies by cancer.
• Methods: Clinical exam, tumor markers (CEA, PSA, CA-125), imaging (CT, PET).
• Tumor Markers: Monitor response/recurrence; rising trend often precedes clinical signs.
• Imaging: For symptoms, ↑ markers, or protocol-based surveillance in high-risk cases.
• Second Primaries: Survivors at increased risk; requires specific, ongoing screening.
• Adherence: Crucial for early detection, impacting prognosis and survivorship care.